XML 36 R26.htm IDEA: XBRL DOCUMENT v3.19.2
Net Income per Share (Tables)
6 Months Ended
Jun. 30, 2019
Earnings Per Share [Abstract]  
Basic and Diluted Net Income per Share
The following table presents the calculation of basic and diluted net income per share (in thousands, except per share information):
 
 
Three Months Ended
June 30,
 
Six Months Ended
June 30,
 
2019
 
2018
 
2019
 
2018
Net income
$
8,528

 
$
5,849

 
$
15,554

 
$
10,778

Basic:
 
 
 
 
 
 
 
Weighted-average shares of common stock outstanding
31,343

 
32,772

 
31,359

 
32,762

Shares used in computing basic net income per share
31,343

 
32,772

 
31,359

 
32,762

Effect of dilutive securities:
 
 
 
 
 
 
 
Restricted stock subject to vesting
495

 
552

 
558

 
576

Shares issuable for acquisition consideration (1)
202

 
565

 
249

 
556

Shares used in computing diluted net income per share
32,040

 
33,889

 
32,166

 
33,894

 
 
 
 
 
 
 
 
Basic net income per share
$
0.27

 
$
0.18

 
$
0.50

 
$
0.33

Diluted net income per share
$
0.27

 
$
0.17

 
$
0.48

 
$
0.32

 
(1)
For the three and six months ended June 30, 2019, this represents the shares held in escrow pursuant to: (i) the Asset Purchase Agreement with Zeon Solutions Incorporated and certain related entities (collectively, “Zeon”); (ii) the Asset Purchase Agreement with RAS & Associates, LLC (“RAS”); (iii) the Asset Purchase Agreement with Southport Services Group, LLC (“Southport”); (iv) the Asset Purchase Agreement with Stone Temple Consulting Corporation (“Stone Temple”); (v) the Agreement and Plan of Merger with Elixiter, Inc. (“Elixiter”); and (vi) the Asset Purchase Agreement with Sundog Interactive, Inc. (“Sundog”), as part of the consideration.  For the three and six months ended June 30, 2018, this represents the shares held in escrow pursuant to: (i) the Asset Purchase Agreement with BioPharm Systems, Inc. (“BioPharm”); (ii) the Asset Purchase Agreement with Zeon; (iii) the Asset Purchase Agreement with RAS; (iv) the Asset Purchase Agreement with Clarity Consulting, Inc. and Truth Labs, LLC (together, “Clarity”); and (v) the Asset Purchase Agreement with So
Antidilutive Securities Excluded from Computation of Earnings Per Share
The number of anti-dilutive securities not included in the calculation of diluted net income per share were as follows (in thousands):
 
Three Months Ended
June 30,
 
Six Months Ended
June 30,
 
2019
 
2018
 
2019
 
2018
Restricted stock subject to vesting

 

 
52

 
60

Convertible senior notes
3,823

 

 
3,823

 

Warrants related to the issuance of convertible senior notes
3,823

 

 
3,823

 

Total anti-dilutive securities
7,646

 

 
7,698

 
60